Mete Kaan BOZKURT, Baykal TÜLEK, Banu BOZKURT, Nalan AKYÜREK, Mehmet ÖZ, Aysel KIYICI

Comparison of the efficacy of prednisolone, montelukast, and omalizumab in an experimental allergic rhinitis model

To compare the efficacy of prednisolone, montelukast, and omalizumab in reducing allergic symptoms and inflammation at tissue level in an experimental allergic rhinitis model. Materials and methods: Forty Sprague Dawley rats were randomized into 5 groups as naive (NS/NC), sensitized/challenged (S/C) by subcutaneous ovalbumin antigen injection, and montelukast-, prednisolone-, and omalizumab-treated groups. A nasal allergen challenge was performed every day from day 20 to day 26. The number of sneezes and nasal/eye rubbing movements, IL-4 and CysLT levels in serum, nasal and bronchoalveolar lavage fluids determined by ELISA, and histopathological findings of nasal mucosa, sinus, and lung tissues were compared. Results: All of the treatments significantly controlled the allergic symptoms of sneezing and nasal/eye rubbing (P < 0.05). IL-4 and CysLT levels on days 20 and 26 were significantly higher in the S/C group compared to the NS/NC group (P < 0.05). Montelukast significantly decreased serum and nasal IL-4 and CysLT levels (P < 0.05), prednisolone decreased nasal lavage IL-4 and CysLT levels (P < 0.05), and omalizumab lowered nasal lavage CysLT levels (P < 0.05). Conclusion: Prednisolone, montelukast, and omalizumab were found to be effective in controlling the allergic symptoms of allergic rhinitis and upper/lower airway inflammation in an experimental allergic rhinitis model.

Anahtar Kelimeler:

Key words: Experimental allergic rhinitis, airway inflammation, prednisolone, montelukast, omalizumab, immunoglobulin E, cysteinyl leukotriene, interleukin-4

Comparison of the efficacy of prednisolone, montelukast, and omalizumab in an experimental allergic rhinitis model

Keywords:

airway inflammation, prednisolone, montelukast, omalizumab, immunoglobulin E, cysteinyl leukotriene, interleukin-4, Experimental allergic rhinitis,

PDF

___

Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, CanonicaGW, van Weel C et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl. 86): 8–160.
Poole JA, Rosenwasser LJ. The role of immunoglobulin E and immune inflammation: implications in allergic rhinitis. Curr Allergy Asthma Rep 2005; 5: 252–8.
Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2010; 125 (Suppl. 2): 73–
Togias A. Rhinitis and asthma: evidence for respiratory system integration. J Allergy Clin Immunol 2003; 111: 1171–83.
Bachert C, Vignola AM, Gevaert P, Leynaert B, Van Cauwenberge P, Bousquet J. Allergic rhinitis, rhinosinusitis, and asthma: one airway disease. Immunol Allergy Clin North Am 2004; 24: 19–43.
Chervinsky P, Philip G, Malice MP, Bardelas J, Nayak A, Marchal JL, Bousquet J, Tozzi CA, Reiss TF. Montelukast for treating fall allergic rhinitis: effect of pollen exposure in 3 studies. Ann Allergy Asthma Immunol 2004; 92: 367–73.
Mucha SM, deTineo M, Naclerio RM, Baroody FM. Comparison of montelukast and pseudoephedrine in the treatment of allergic rhinitis. Arch Otolaryngol Head Neck Surg 2006; 132: 164–72.
Milgrom H, Fick RB, Su JQ, Reimann JD, Bush RK, Watrous ML, Metzger WJ. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 1999; 341: 1966–73.
Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004; 125: 1378–86.
Djukanović R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Bao W, Fowler-Taylor A, Matthews J, Busse WW et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170: 583–93. van Rensen EL, Evertse CE, van Schadewijk WA, van Wijngaarden S, Ayre G, Mauad T, Hiemstra PS, Sterk PJ, Rabe KF. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy. 2009; 64: 72–80.
Prieto L, Gutiérrez V, Colás C, Tabar A, Pérez-Francés C, Bruno L, Uixera S. Effect of omalizumab on adenosine 5’-monophosphate responsiveness in subjects with allergic asthma. Int Arch Allergy Immunol 2006; 139: 122–31.
Wu AY, Chik SC, Chan AW, Li Z, Tsang KW, Li W. Antiinflammatory effects of high-dose montelukast in an animal model of acute asthma. Clin Exp Allergy 2003; 33: 359–66.
Henderson WR, Chiang GK, Tien Y, Chi EY. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med 2006; 173: 718–28.
Muz MH, Deveci F, Bulut Y, Ilhan N, Yekeler H, Turgut T. The effects of low dose leukotriene receptor antagonist therapy on airway remodeling and cysteinyl leukotriene expression in a mouse asthma model. Exp Mol Med 2006; 38: 109–18.
Roa J, Morikawa H, Crawford L, Baatjes A, Duong M, Denburg JA. The effects of montelukast on tissue inflammatory and bone marrow responses in murine experimental allergic rhinitis: interaction with interleukin-5 deficiency. Immunol 2007; 122: 438–44.
Harrison S, Gatti R, Baraldo S, Oliani KL, Andre E, Trevisani M, Gazzieri D, Saetta M, Geppetti P. Montelukast inhibits inflammatory responses in small airways of the Guinea-pig. Pulm Pharmacol Therapeut 2008; 21: 317–23.
Taylor IK, Shaw RJ. The mechanism of action of corticosteroids in asthma. Respir Med 1993; 87: 261–7.
Narita S, Asakura K, Kataura A. Effects of thromboxane A2 receptor antagonist (Bay u 3405) on nasal symptoms after antigen challenge in sensitized guinea pigs. Int Arch Allergy Immunol 1996; 109: 161–6.
Busse WW. Leukotrienes and inflammation. Am J Respir Crit Care Med 1998; 157: S210–3.
Henderson WR Jr, Tang LO, Chu SJ, Tsao SM, Chiang GKS, Jones F, Jonas M, Pae C, Wang H, Chi EY. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med 2002; 165: 108–16.
Shaw RJ, Fitzharris P, Cromwell O, Wardlaw AJ, Kay AB. Allergen-induced release of sulphidopeptide leukotrienes and LTB4 in allergic rhinitis. Allergy 1985; 40: 1–6.
Mizutani N, Nabe T, Imai A, Sakurai H, Takenaka H, Kohno S. Markedly increased nasal blockage by intranasal leukotriene D4 in an experimental allergic rhinitis model: contribution of dilated mucosal blood vessels. Jpn J Pharmacol 2001; 86, 170–
Underwood DC, Osborn RR, Newsholme SJ, Torphy TJ, Hay DW. Persistent airway eosinophilia after leukotriene (LT) D4 administration in the guinea pig: modulation by the LTD4 receptor antagonist, pranlukast, or an interleukin-5 monoclonal antibody. Am J Respir Crit Care Med 1996; 154: 850–
Shimizu T, Hirano H, Majima Y, Sakakura Y. A mechanism of antigen-induced mucus production in nasal epithelium of sensitized rats. A comparison with lipopolysaccharide-induced mucus production. Am J Respir Crit Care Med 2000; 161: 1648–54.
Holm AF, Godthelp T, Fokkens WJ, Severijnen EA, Mulder PG, Vroom TM, Rijnties E. Long-term effects of corticosteroid nasal spray on nasal inflammatory cells in patients with perennial allergic rhinitis. Clin Exp Allergy 1999; 29: 1356–66. Jacobson MR, Juliusson S, Löwhagen O, Balder B, Kay AB, Durham SR. Effect of topical corticosteroids on seasonal increases in epithelial eosinophils and mast cells in allergic rhinitis: a comparison of nasal brush and biopsy methods. Clin Exp Allergy 1999; 29: 1347–55.
Braunstahl GJ, Fokkens WJ, Overbeek SE, KleinJan A, Hoogsteden HC, Prins JB. Mucosal and systemic inflammatory changes in allergic rhinitis and asthma: a comparison between upper and lower airways. Clin Exp Allergy 2003; 33: 579–87.
McCusker C, Chicoine M, Hamid Q, Mazer B. Site-specific sensitization in a murine model of allergic rhinitis: role of the upper airway in lower airways disease. J Allergy Clin Immunol 2002; 110: 891–8.
Jeffery PK. Pathology of asthma. Br Med Bull 1992; 48: 23–39.
Brozmanova M, Plevkova J, Bartos V, Plank L, Tatar M. Antileukotriene treatment and allergic rhinitis-related cough in guinea pigs. J Physiol Pharmacol 2005; 56 (Suppl. 4): 21–30. Careau E, Sirois J, Bissonnette EY. Characterization of lung hyperresponsiveness, inflammation, and alveolar macrophage mediator production in allergy resistant and susceptible rats. Am J Respir Cell Mol Biol 2002; 26: 579–86.